John Elrod, PhD
Director, Research Development, Center for Translational Medicine
Associate Professor, Cardiovascular Sciences
Associate Professor, Center for Translational Medicine
Associate Professor, Alzheimer's Center at Temple
- Contact Information
- About Me
The Elrod laboratory is focused on two complimentary lines of research--the first being the identification of genetic components of mitochondrial calcium exchange and their role in cellular physiology and heart disease and the second being the utilization of genome-wide functional screening to discover novel modulators of the necrotic cell death program.
Heart failure and myocardial infarction, as well as many other diseases, are characterized by significant metabolic dysfunction and cell death, both of which have been shown to initiate and drive disease. Mitochondrial calcium signaling is a nexus for these processes regulating both oxidative phosphorylation (ATP production) and cell death. While much is known about how calcium exchange is regulated at the plasma membrane, our understanding of the mitochondrial calcium pool remains elementary. The lab utilizes in vitro and in vivo techniques including real-time measurements of calcium exchange in isolated cells and genetically engineered mice in clinically relevant disease models to dissect the molecular role of novel genes.
Historically, necrotic cell death (characterized by cell swelling, membrane rupture, lysis and inflammation) has largely been thought to be a non-specific-unprogrammed process and thereby void of distinct signaling events and genetic players. Recently, it has become clear that necrosis, like apoptosis, may be highly regulated and involve specific gene programs. To discover novel modulators of necrosis, we have utilized genome-wide functional screening in cell-based assay systems (shRNA lentiviral library). Using a "system biology" approach, we have identified unique players and pathways in cell death and are investigating their mechanisms of action.
The ultimate goal of the Elrod lab is to discover new therapeutic avenues for the treatment of disease with a focus towards myocardial infarction and heart failure.
- Education, Training & Credentials
- Kirschstein Fellow, Cincinnati Children's Medical Hospital, Howard Hughes Medical Institute, 2012 - Laboratory of Dr. Jeffrey Molkentin
- PhD, Pathology, Albert Einstein College of Medicine, 2007
- BS, Biology (cum laude), Centenary College, 2002
- Basic Science Council, American Heart Association
- International Society for Heart Research
- American Physiological Society
- Related Links